Your browser doesn't support javascript.
loading
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
Gao, Jennifer J; Cheng, Joyce; Prowell, Tatiana M; Bloomquist, Erik; Tang, Shenghui; Wedam, Suparna B; Royce, Melanie; Krol, Danielle; Osgood, Christy; Ison, Gwynn; Sridhara, Rajeshwari; Pazdur, Richard; Beaver, Julia A; Amiri-Kordestani, Laleh.
Afiliação
  • Gao JJ; Oncology Center of Excellence, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. Electronic address: jennifer.gao@fda.hhs.gov.
  • Cheng J; Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Prowell TM; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Bloomquist E; Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Tang S; Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Wedam SB; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Royce M; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Krol D; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Osgood C; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Ison G; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Sridhara R; Oncology Center of Excellence, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Pazdur R; Oncology Center of Excellence, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Beaver JA; Oncology Center of Excellence, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Amiri-Kordestani L; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Lancet Oncol ; 22(11): 1573-1581, 2021 11.
Article em En | MEDLINE | ID: mdl-34656225
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Quinase 4 Dependente de Ciclina / Quinase 6 Dependente de Ciclina / Fulvestranto Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Quinase 4 Dependente de Ciclina / Quinase 6 Dependente de Ciclina / Fulvestranto Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido